Epigenetic abnormalities in myeloproliferative neoplasms: A target for novel therapeutic strategies

Clinical Epigenetics

Volumn 2, Issue 2, 2011, Pages 197-212

  Mascarenhas, John ^a   Roper, Nitin ^a   Chaurasia, Pratima ^a   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ASXL1; DNA methyltransferase inhibitor; EZH2; Histone deacetylase inhibitor; IDH1 2; IKZF; JAK2; Myeloproliferative neoplasm; TET2

Indexed keywords

3 DEAZANEPLANOCIN A; 5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; AZACITIDINE; BUSULFAN; CLADRIBINE; CYT 387; GEMTUZUMAB OZOGAMICIN; GIVINOSTAT; HISTONE DEACETYLASE GENE; HYDROXYUREA; INCYTE; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LESTAURTINIB; MELPHALAN; PANOBINOSTAT; PHENYLALANINE; PLACEBO; PREDNISONE; RUXOLITINIB; SB 1518; TG 101348; THALIDOMIDE; UNCLASSIFIED DRUG; VALINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADDITIONAL SEX COMBS LIKE 1 GENE; BONE MARROW SUPPRESSION; CPG ISLAND; CXC CHEMOKINE RECEPTOR 4 GENE; DNA METHYLATION; DNA MODIFICATION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENHANCER OF ZESTE HOMOLOG 2 GENE; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IKAROS FAMILY ZINC FINGER 1 GENE; INCIDENCE; JANUS ASSOCIATED KINASE 2 GENE; LOW DRUG DOSE; MOLECULAR PATHOLOGY; MUTATION RATE; MUTATOR GENE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONSET AGE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHLEBOTOMY; POLYCYTHEMIA RUBRA VERA 1 GENE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN ARGININE METHYLTRANSFERASE 5 GENE; REGULATOR GENE; REVIEW; SECRETED FRIZZLED RELATED PROTEIN 1 GENE; SECRETED FRIZZLED RELATED PROTEIN 2 GENE; SUPPRESSOR OF CYTOKINE SIGNALING GENE; TEN TO 11 TRANSLOCATION 2 GENE; THROMBOCYTHEMIA; UPREGULATION;

EID: 84856271833     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1007/s13148-011-0050-6     Document Type: Review

References (163)

1. Abdel-Wahab O, Manshouri T et al (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70(2):447-452
2. Abdel-Wahab O, Pardanani A et al (2010) Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. ASH Annu Meet Abstr 116(21):3070
3. Akada H, Hamada S et al (2010) Efficacy of vorinostat in a murine model of polycythemia vera. ASH Annu Meet Abstr 116(21):629
4. Al-Ameri AA-A, Kantarjian H et al (2010) Decitabine and gemtuzumab ozogamicin in patients with advanced myelofibrosis. ASH Annu Meet Abstr 116(21):5061
5. Ambros V (2004) The functions of animal microRNAs. Nature 431 (7006):350-355 (Pubitemid 39265675)
6. Aviram A, Witenberg B et al (2003) Detection of methylated ABL1 promoter in Philadelphia-negative myeloproliferative disorders. Blood Cells Mol Dis 30(1):100-106 (Pubitemid 36378871)
7. Barosi G, Bordessoule D et al (2005) Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 106 (8):2849-2853 (Pubitemid 41510763)
8. Baskind HA, Na L et al (2009) Functional conservation of Asxl2, a murine homolog for the Drosophila enhancer of trithorax and Polycomb group gene Asx. PloS One 4(3):e4750
9. Baxter EJ, Scott LM et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (9464):1054-1061 (Pubitemid 40386783)
10. Becker PB, Horz W (2002) ATP-dependent nucleosome remodeling. Annu Rev Biochem 71:247-273 (Pubitemid 34800221)
11. Beer PA, Campbell PJ et al (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112(1):141-149
12. Bennemann K, Schubert C et al (2010) Epigenetic downregulation of secreted Frizzled-related proteins in Philadelphia positive and Philadelphia negative myeloproliferative neoplasms. ASH Annu Meet Abstr 116(21):4647
13. Berdasco M, Esteller M (2010) Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 19(5):698-711
14. Biancotto C, Frige G et al (2010) Histone modification therapy of cancer. Adv Genet 70:341-386
15. Bishton MJ, Harrison SJ et al (2011) Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitorinduced thrombocytopenia. Blood 117(13):3658-3668
16. Bogani C, Ponziani V et al (2008) Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 26(8):1920-1930
17. Branscombe TL, Frankel A et al (2001) PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J Biol Chem 276(35):32971-32976
18. Bruchova H, Yoon D et al (2007) Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 35 (11):1657-1667 (Pubitemid 47633777)
19. Bumm TGP, Elsea C et al (2006) Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Research 66(23):11156-11165 (Pubitemid 46009942)
20. Calin GA, Liu CG et al (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 101(32):11755-11760 (Pubitemid 39095368)
21. Calin GA, Ferracin M et al (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353(17):1793-1801 (Pubitemid 41549891)
22. Cao R, Zhang Y (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14(2):155-164 (Pubitemid 38520143)
23. Capello D, Deambrogi C et al (2008) Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 141(4):504-511 (Pubitemid 351550557)
24. Carbuccia N, Murati A et al (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23(11):2183-2186
25. Cervantes F, Alvarez-Larrán A et al (2005) Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 129(6):771-775 (Pubitemid 40904527)
26. Cervantes F, Alvarez-Larrán A et al (2006) Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 134(2):184-186 (Pubitemid 43893910)
27. Cervantes F, Dupriez B et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895-2901
28. Chang JC, Gross HM (1988) Remission of chronic idiopathic myelofibrosis to busulfan treatment. Am J Med Sci 295(5):472-476
29. Chase A, Cross NC (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17(9):2613-2618
30. Chou WC, Hou HA et al (2010) Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115(14):2749-2754
31. Dang L, White DW et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739-744
32. Danilov AV, Relias Vet al (2009) Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 145(1):131-132
33. Dawson MA, Bannister AJ et al (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461 (7265):819-822
34. DeAngelo DJ, Tefferi A et al (2010) A phase II trial of Panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. ASH Annu Meet Abstr 116(21):630
35. Debernardi S, Skoulakis S et al (2007) MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 21(5):912-916 (Pubitemid 46672066)
36. Deininger MW, Goldman JM et al (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343-3356
37. Delhommeau F, Dupont S et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360(22):2289-2301
38. Deng S, Calin GA et al (2008) Mechanisms of microRNA deregulation in human cancer. Cell Cycle 7(17):2643-2646
39. Dingli D, Schwager SM et al (2006) Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 106(3):623-630 (Pubitemid 43157626)
40. Dupriez B, Morel P et al (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88(3):1013-1018 (Pubitemid 26333326)
41. Ernst T, Chase AJ et al (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42 (8):722-726
42. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8(4):286-298 (Pubitemid 46439286)
43. Esteller M (2008) Epigenetics in cancer. The New England Journal of Medicine 358(11):1148-1159
44. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4(2):143-153 (Pubitemid 38198742)
45. Fernandez-Mercado M, Cebrian Vet al (2008) Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms. Leuk Res 32 (10):1638-1640
46. Figueroa ME, Abdel-Wahab O et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553-567
47. Fisher CL, Berger J et al (2003) A human homolog of additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. Gene 306:115-126 (Pubitemid 36351400)
48. Fisher CL, Lee I et al (2010a) Additional sex combs-like 1 belongs to the enhancer of trithorax and Polycomb group and genetically interacts with Cbx2 in mice. Dev Biol 337(1):9-15
49. Fisher CL, Pineault N et al (2010b) Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115(1):38-46
50. Fiskus W, Wang Yet al (2009) Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor Panobinostat against human AML cells. Blood 114(13):2733-2743
51. Fourouclas N, Li J et al (2008) Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 93(11):1635-1644
52. Georgantas RW 3rd, Hildreth R et al (2007) CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A 104 (8):2750-2755 (Pubitemid 46327951)
53. Georgopoulos K (2002) Haematopoietic cell-fate decisions, chromatin regulation and Ikaros. Nat Rev Immunol 2(3):162-174 (Pubitemid 37328763)
54. Girardot M, Pecquet C et al (2010) miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 116(3):437-445
55. Gramantieri L, Ferracin M et al (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67(13):6092-6099 (Pubitemid 47037488)
56. Green A, Beer P (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362(4):369-370
57. Greenhalgh CJ, Hilton DJ (2001) Negative regulation of cytokine signaling. J Leukoc Biol 70(3):348-356 (Pubitemid 32826121)
58. Guerini V, Barbui V et al (2008) The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 22(4):740-747 (Pubitemid 351552623)
59. Haberland M, Montgomery RL et al (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10(1):32-42
60. Havelange V, Garzon R (2010) MicroRNAs: emerging key regulators of hematopoiesis. Am J Hematol 85(12):935-942
61. Hexner E, Goldberg JD et al (2009) A multicenter, open label phase I/II study of CEP701 (Lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the myeloproliferative disorders research consortium (MPD-RC). ASH Annu Meet Abstr 114(22):754
62. Hochhaus A, O'Brien SG et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054-1061
63. Hoffman R (2005) Hematology: basic principles and practice. Elsevier Churchill Livingstone, Philadelphia
64. Hoffman R, Rondelli D (2007) Biology and treatment of primary myelofibrosis. Hematology Am Soc Hematol Educ Program 2007:346-354
65. Hussein K, Theophile K et al (2009) MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. Platelets 20(6):391-400
66. Hussein K, Abdel-Wahab O et al (2010) Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol 85(1):81-83
67. Iacobucci I, Storlazzi CT et al (2009) Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114(10):2159-2167
68. Iancu-Rubin C, Feller F et al (2010) Targeting non-histone protein acetylation impairs platelet production during normal megakaryocytopoiesis. ASH Annu Meet Abstr 116(21):2610
69. Ihalainen J, Juvonen E et al (1994) Calcitonin gene methylation in chronic myeloproliferative disorders. Leukemia 8(2):230-235 (Pubitemid 24057535)
70. Ito S, D'Alessio AC et al (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466(7310):1129-1133
71. Jager R, Gisslinger H et al (2010) Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 24(7):1290-1298
72. James C, Ugo Vet al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (7037):1144-1148 (Pubitemid 40663494)
73. Jelinek J, Li J et al (2007) Epigenetic control of PRV-1 expression on neutrophils. Exp Hematol 35(11):1677-1683
74. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532):1074-1080 (Pubitemid 32758077)
75. Jones LC, Tefferi A et al (2004) RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 23(47):7846-7853 (Pubitemid 39457034)
76. Jost E, Do ON et al (2007) Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABLnegative myeloproliferative disorders. Leukemia 21(3):505-510
77. Kantarjian HM, O'Brien S et al (2007) Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109(6):1133-1137 (Pubitemid 46435392)
78. Klippel S, Strunck E et al (2002) Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood 100(7):2441-2448
79. Kondo Y, Shen L et al (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40(6):741-750 (Pubitemid 351748874)
80. Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693-705 (Pubitemid 46273577)
81. Kralovics R, Passamonti F et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine 352(17):1779-1790 (Pubitemid 40570926)
82. Kroger N, Holler E et al (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114(26):5264-5270
83. Kumagai T, Tefferi A et al (2005) Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res 29(5):511-515 (Pubitemid 40327239)
84. Lacout C, Pisani DF et al (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108(5):1652-1660 (Pubitemid 44316134)
85. Lawrie CH (2007) MicroRNAs and haematology: small molecules, big function. Br J Haematol 137(6):503-512 (Pubitemid 46817340)
86. Lee J (2009) Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. Ann Hematol 88 (7):699-700
87. Levine RL, Wadleigh M et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387-397 (Pubitemid 40544655)
88. Liu F, Zhao X et al (2011) JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19(2):283-294
89. Mani S, Herceg Z (2010) DNA demethylating agents and epigenetic therapy of cancer. Adv Genet 70:327-340
90. Mascarenhas J (2009) Risk adapted approach to the treatment of primary myelofibrosis. Hematology Education E H Association 14:192-199
91. Mascarenhas J, Wang X et al (2009) A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post-PV/ET MF). ASH Annu Meet Abstr 114(22):308
92. Mascarenhas J, Navada S et al (2010) Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res 34(9):1246-1249
93. Meng F, Henson R et al (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2):647-658 (Pubitemid 47187346)
94. Mesa RA, Steensma DP et al (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101(7):2534-2541 (Pubitemid 36857609)
95. Mesa RA, Kantarjian H et al (2009a) Validation of the serial use of the myelofibrosis symptom assessment form (MF-SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial. ASH Annu Meet Abstr 114(22):3917
96. Mesa RA, Verstovsek S et al (2009b) 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 23(1):180-182
97. Mesa RA, Yao X et al (2010) Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 116(22):4436-4438
98. Metivier R, Gallais R et al (2008) Cyclical DNA methylation of a transcriptionally active promoter. Nature 452(7183):45-50 (Pubitemid 351355084)
99. Moliterno AR, Hexner E et al (2009) An open-label study of CEP-701 in patients with JAK2 V617F-positive PVand ET: update of 39 enrolled patients. ASH Annu Meet Abstr 114(22):753
100. Morin RD, Johnson NA et al (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42(2):181-185
101. Nagy E, Beck Z et al (2003) Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer 39 (16):2298-2305 (Pubitemid 37214853)
102. Nischal S, Zhou L et al (2010) Epigenomic profiling of myeloproliferative diseases reveal idiopathic myelofibrosis as an epigeneti cally distinct subgroup and highlights the epigenetic effects of Jak2V617F mutation. ASH Annu Meet Abstr 116(21):627
103. O'Brien SG, Guilhot F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine 348(11):994-1004 (Pubitemid 36302244)
104. Odenike OM, Godwin JE et al (2008) Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. ASH Annu Meet Abstr 112(11):2809
105. Pardanani AD, Levine RL et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108(10):3472-3476
106. Pardanani A, Gotlib JR et al (2010a) Longer-term follow up with TG101348 therapy in myelofibrosis confirms sustained improvement in splenomegaly, disease-related symptoms, and JAK2V617F allele burden. ASH Annu Meet Abstr 116(21):459
107. Pardanani A, George G et al (2010b) A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. ASH Annu Meet Abstr 116(21):460
108. Pardanani A, Lasho TL et al (2010c) IDH1 and IDH2 mutation analysis in chronic-and blast-phase myeloproliferative neoplasms. Leukemia 24(6):1146-1151
109. Passamonti F, Rumi E et al (2008) A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111(7):3383-3387
110. Passamonti F, Cervantes F et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWGMRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703-1708
111. Pehlivan M, Sercan Z et al (2009) sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia. Leuk Res 33(8):1062-1067
112. Petti MC, Latagliata R et al (2002) Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 116 (3):576-581 (Pubitemid 34178656)
113. Quentmeier H, Geffers R et al (2008) SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22 (12):2169-2175
114. Quintas-Cardama A, Tong W et al (2008) A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 22(5):965-970 (Pubitemid 351689878)
115. Quintas-Cardama A, Vaddi K et al (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109-3117
116. Rambaldi A, Dellacasa CM et al (2010) A pilot study of the histonedeacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150(4):446-455
117. Rondelli D, Boyer MW, Isola LM, Shore T, Bacigalupo A, Klisovic RB, Marchioli R, Goldberg JD, Hoffman R, Silverman LR (2010) First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: interim analysis of MPD-RC 101 protocol. J Clin Oncol 28:15s
118. Rosti V, Massa M et al (2007) The expression of CXCR4 is downregulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis 38(3):280-286 (Pubitemid 46518174)
119. Rozman C, Giralt M et al (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67 (10):2658-2663
120. Santos FPS, Kantarjian HM et al (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or postpolycythemia vera/essential thrombocythemia myelofibrosis. Blood 115(6):1131-1136
121. Schaub FX, Looser R et al (2010) Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115(10): 2003-2007
122. Schaub FX, Lehmann Tet al (2011) Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood 117(6):2075-2076
123. Scherber R, Mesa RA (2011) Future therapies for the myeloproliferative neoplasms. Curr Hematol Malig Rep 6(1):22-27
124. Scott LM, Tong W et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England Journal of Medicine 356(5):459-468 (Pubitemid 46193073)
125. Shi J, Zhao Yet al (2007) Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 67(13):6417-6424 (Pubitemid 47037526)
126. Silverman LR, Demakos EP et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (10):2429-2440 (Pubitemid 34525728)
127. Silverman LR, McKenzie DR et al (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24(24):3895-3903 (Pubitemid 46630737)
128. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647(1-2):21-29
129. Skov V, Larsen TS et al (2010a) Enhanced gene expression of EZH2 in patients with primary myelofibrosis. ASH Annu Meet Abstr 116(21):4118
130. Skov V, Larsen TS et al (2010b) Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. ASH Annu Meet Abstr 116 (21):4119
131. Spange S, Wagner T et al (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41(1):185-198
132. Stegelmann F, Schlenk RF et al (2010) Mutations of EZH2 in myeloproliferative neoplasms with myelofibrosis: correlation with molecular and clinical data. ASH Annu Meet Abstr 116 (21):4111
133. Suzuki R, Onizuka M et al (2007) Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders. Tokai J Exp Clin Med 32(4):131-135
134. Swierczek S, Yoon D et al (2010) MicroRNA-101 is down-regulated in PV and ET granulocytes and its decrease is associated with over-expression of histone methyltransferase in EZH2 in MPN patients. ASH Annu Meet Abstr 116(21):1989
135. Swierczek SI, Yoon D et al (2011) Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera. Haematologica 96:775-778
136. Tahiliani M, Koh KP et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929):930-935
137. Tam CS, Kantarjian H et al (2009) Dynamic model for predicting death within 12 months in patients with primary or postpolycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 27(33):5587-5593
138. Tefferi A (2000) Myelofibrosis with myeloid metaplasia. The New England Journal of Medicine 342(17):1255-1265 (Pubitemid 30235956)
139. Tefferi A, Silverstein MN et al (1997) 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 99(2):352-357 (Pubitemid 27497566)
140. Tefferi A, Barosi G et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108(5):1497-1503 (Pubitemid 44316114)
141. Tefferi A, Huang J et al (2007a) Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 109(10):2083-2088 (Pubitemid 46744203)
142. Tefferi A, Thiele J et al (2007b) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092-1097 (Pubitemid 47281402)
143. Tefferi A, Lim KH et al (2009a) Mutation in TET2 in myeloid cancers. N Engl J Med 361(11):1117-1118
144. Tefferi A, Pardanani A et al (2009b) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23(5):905-911
145. Tefferi A, Lasho TL et al (2010) IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24(7):1302-1309
146. Teofili L, Martini M et al (2008) Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 123(7):1586-1592
147. Thiele J, Kvasnicka HM (2009) The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 4(1):33-40
148. Tsiara SN, Chaidos A et al (2007) Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematologica 117(3):156-161 (Pubitemid 46496799)
149. Vannucchi AM, Antonioli E et al (2008) Characteristics and clinical correlates of MPL 515 W>L/K mutation in essential thrombocythemia. Blood 112(3):844-847
150. Venturini L, Battmer K et al (2007) Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 109(10):4399-4405 (Pubitemid 46743409)
151. Verstovsek S, Silver RTet al (2006) JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 20(11):2067 (Pubitemid 44614909)
152. Verstovsek S, Odenike O et al (2009) Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. ASH Annu Meet Abstr 114(22):3905
153. Verstovsek S, Kantarjian H et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117-1127
154. Wang JC, Chen W et al (2002) Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol 116(3):582-586 (Pubitemid 34178657)
155. Wang X, Zhang Wet al (2009a) Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res 69(19):7612-7618
156. Wang Y, Fiskus Wet al (2009b) Cotreatment with Panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114(24):5024-5033
157. Wang X, Zhang Wet al (2010) Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatinmodifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood 116(26):5972-5982
158. Wernig G, Mercher T et al (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107(11):4274-4281 (Pubitemid 43801351)
159. Westman BJ, Mackay JP et al (2002) Ikaros: a key regulator of haematopoiesis. Int J Biochem Cell Biol 34(10):1304-1307 (Pubitemid 34804365)
160. Willert K, Brown JD et al (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423(6938): 448-452 (Pubitemid 36626997)
161. Wolanskyj AP, Schwager SM et al (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proc 81(2):159-166 (Pubitemid 43205767)
162. Yan H, Parsons DWet al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765-773
163. Zaleskas VM, Krause DS et al (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PloS One 1:e18